The Food and Drug Administration on Friday granted expedited review to three experimental psychedelic drugs for major depression and PTSD, a move the Trump administration says could shorten decisions from about a year to just a few months. For clinicians, that raises the odds of the first FDA-approved psychedelic therapies arriving soon — while leaving the usual safety, efficacy and implementation questions squarely in play.

The Move

• FDA issued priority review vouchers tied to three experimental products: Compass Pathways’ synthetic psilocybin for treatment-resistant depression, Usona Institute’s psilocybin program for major depressive disorder, and Transcend Therapeutics’ methylone for PTSD.

• FDA Commissioner Marty Makary said the agency could potentially approve the first psychedelic drug by the end of summer.

• The voucher program, launched last year, is designed to cut FDA review time from roughly 12 months to a matter of months.

Why it Matters for Care

• Psychiatry, primary care and behavioral health clinicians may soon face patient questions about regulated psychedelic options for treatment-resistant depression, Major depressive disorder (MDD), and PTSD.

• Expedited review changes the timeline, not the evidentiary bar: companies still must show safety and effectiveness, especially given prior concerns about abuse potential, cardiovascular risk and trial quality in this drug class.

• If approvals come, health systems will need protocols for patient selection, monitoring, adverse-event management and referral pathways for supervised treatment.

Between the Lines

• The policy shift reflects growing political support from the Trump administration and veterans advocates, who have pushed for faster access to alternative mental health treatments.

• It also comes one day after the Justice Department said it would ease restrictions on state-licensed medical marijuana, underscoring a broader willingness to revisit drugs that also produce a high.

• Critics argue the voucher program was created without congressional input and could strain trust in the FDA if the process appears politicized or vulnerable to influence.

What to Watch

• Whether FDA actually clears a psychedelic therapy by the end of summer — and for which indication first: depression or PTSD.

• How closely the agency scrutinizes trial design and safety after its 2024 rejection of MDMA for PTSD.

• Whether the administration’s new executive push on psychedelic research expands U.S. trials, including work on noribogaine for alcohol use disorder.

Source: NBC News Health